8 Most Undervalued Healthcare Stocks to Buy According to Analysts

5. Pfizer Inc. (NYSE:PFE)

Price Target Upside: 31.92%

Pfizer Inc. (NYSE:PFE) stands fifth on our list of the most undervalued stocks. It is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. In developing and emerging markets, it promotes wellness, prevention, treatment, and cures. The company wants to become a leading cancer organization in the world. With intentions to keep improving over the next ten years, it is currently the third-largest biopharma firm in the US for cancer.

With a dividend yield of 6.3%, Pfizer Inc. (NYSE:PFE) outperforms the majority of blue-chip stocks. Its management recently announced a 2.4% increase in early December, reaffirming its intention to support and grow this dividend on a recurrent basis.

Pfizer Inc. (NYSE:PFE) is concentrating on its oncology pipeline for future growth with the addition of multiple new blockbuster medications to its portfolio as part of its 2030 targets. It is anticipated that the business would keep searching for chances to buy out promising pharmaceutical firms in order to expand its pipeline. It spent a large amount of its pandemic profits on the $43 billion purchase of the oncology-focused biotech startup Seagen.

The company is seeing good results from this approach, as management projects earnings growth of 10% to 18% in 2025. Additionally, analysts predict that over the next three to five years, the company’s earnings will increase by about 14% yearly.